Reviewing BiondVax Pharmaceuticals Ltd. (BVXV)’s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)’s results

This is a contrast between BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) based on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BiondVax Pharmaceuticals Ltd. N/A 0.00 N/A -2.30 0.00
OHR Pharmaceutical Inc. N/A 0.00 13.24M -0.22 0.00

Table 1 highlights BiondVax Pharmaceuticals Ltd. and OHR Pharmaceutical Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us BiondVax Pharmaceuticals Ltd. and OHR Pharmaceutical Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
BiondVax Pharmaceuticals Ltd. 0.00% 0% 0%
OHR Pharmaceutical Inc. 0.00% -62.7% -54.6%

Insider and Institutional Ownership

The shares of both BiondVax Pharmaceuticals Ltd. and OHR Pharmaceutical Inc. are owned by institutional investors at 0% and 14.6% respectively. About 22.93% of BiondVax Pharmaceuticals Ltd.’s share are held by insiders. Insiders Competitively, held 8.91% of OHR Pharmaceutical Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BiondVax Pharmaceuticals Ltd. -8.47% 1.5% -7.9% -16.54% 0.75% 0.75%
OHR Pharmaceutical Inc. -5.33% -32.38% -25.58% -34.41% -90.21% -92.37%

For the past year BiondVax Pharmaceuticals Ltd. has 0.75% stronger performance while OHR Pharmaceutical Inc. has -92.37% weaker performance.

Summary

BiondVax Pharmaceuticals Ltd. beats on 4 of the 6 factors OHR Pharmaceutical Inc.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.